Journal article
CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium
Abstract
5519
Authors
Welch S; Hirte H; Elit L; Schilder RJ; Pond G; Kovacs J; Wright J; Oza AM
Journal
Journal of Clinical Oncology, Vol. 25, No. 18_suppl, pp. 5519–5519
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2007
DOI
10.1200/jco.2007.25.18_suppl.5519
ISSN
0732-183X